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Abstract Invasive lobular carcinoma (ILC) and lobular neo-
plasia (LN) are two distinct conditions that still pose chal-
lenges regarding to their classification, diagnosis and manage-
ment. Although they share similar cellular characteristics,
such as discohesive neoplastic cells and absence of e-
cadherin staining, they represent completely different condi-
tions. LN encompasses atypical lobular hyperplasia (ALH)
and lobular carcinoma in situ (LCIS), which are currently
considered risk factors and non-obligatory precursors of breast
neoplasia. These lesions are diagnosed as incidental findings
in percutaneous biopsies or appear as non-specific clusters of
punctate calcifications in mammograms. ILC is the second
most common breast malignancy and has typical histological
features, such as infiltrative growth and low desmoplasia.
These histological features are reflected in imaging findings
and constitute the reasons for typical subtle mammographic
features of ILC, as architectural distortion or focal
asymmetries. Ultrasonography (US) may detect almost 75 %
of the ILCs missed by mammography and represents the
modality of choice for guiding biopsies. Magnetic resonance
imaging (MRI) exhibits a high sensitivity for the diagnosis of
ILC and for detecting synchronous lesions.
Teaching Points
• LN includes ALH and LCIS, risk factors and non-obligatory
precursors of breast cancer.
• Absence of e-cadherin staining is crucial for differentiation
among ductal and lobular lesions.
• ILC has typical histological features, such as infiltrative
growth and low desmoplasia.
• Mammographic features of ILC are often subtle and reflect
the histological features.
• MRI exhibits a high sensitivity for the diagnosis of ILC and
for detecting synchronous lesions.
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Introduction
Although invasive lobular carcinoma (ILC) and lobular neo-
plasia (LN) have been described and recognised for many
years, their classifications continue to be controversial, creat-
ing diagnostic problems and debates concerning the most
appropriate treatment and follow-up for these patients [1, 2].
The role and implications of LN in the physiopathology
and development of breast cancer are not fully understood [3].
In addition, the majority of cases have no clinical signs or
imaging features, making this a challenging diagnosis. With
the increasing number of core needle biopsies, diagnosis of
LN has become more frequent, increasing the necessity for
improvements in the knowledge of the different aspects
influencing the decision toward surgical excision or conser-
vative management [1, 2].
ILC represents approximately 5–15 % of all breast carci-
nomas and exhibits challenging characteristics, such as low
sensitivity in screening examinations, tumour size underesti-
mation in both mammograms and clinical examinations, and a
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high prevalence of synchronous lesions [4]. Knowledge of the
main imaging findings, as well as of the imaging limitations,
may contribute to an early diagnosis and more effective
therapies.
This article reviews the concepts of ILC and LN and their
main histological variants. Their clinical, histopathological,
and imaging features are indicated emphasising the key path-
ological and radiological findings for most accurate patient
therapeutic decisions and follow-up.
Lobular neoplasia
Background
Lobular carcinoma in situ (LCIS) was first documented by
Ewing in 1919 and was described by Foote and Stewart in
1941 [5].
In 1978, Haagensen proposed the term “lobular neoplasia”
to group two histologically similar lobular proliferations:
atypical lobular hyperplasia (ALH) and LCIS. In fact, rather
than including two proliferative diseases, LN encompasses a
continuum between these two lesions [1, 4].
The distinction between ALH and LCIS is based on
the degree of acini involvement. According to Page
et al., LCIS should be used to define cellular prolifera-
tions involving and distending more than half of the
lobular unit. ALH is used to define proliferations when
the criteria for LICS are not met and when less than
half of a lobular unit is involved (Fig. 1) [4].
In the 1970s, Haagensen, Rosen and Page described LCIS
as a risk factor for breast cancer, emphasising its indolent
behaviour and its interval of 15–20 years before becoming
an invasive lesion. However, they had already noticed that
LCIS lead to invasive progression less frequently than high-
grade ductal carcinoma in situ (DCIS), confirming a distinct
biological behaviour [1].
Currently, it is estimated that ALH increases the risk
for breast cancer approximately fourfold to fivefold,
whereas LCIS is accompanied by a ninefold to tenfold
increase [3]. The risk is higher in women with breast
carcinoma family history [2].
The concept that LN does not constitute a true pre-
neoplastic lesion, but rather represents a risk factor, was
supported by evidence showing that LN increases the risk of
cancer in both breasts, the most common histological type of
which is invasive ductal carcinoma (IDC) [1, 3].
However, new evidence from molecular and genetic anal-
yses also points to a precursor role for LN based on the
following: (1) the 3-times-greater risk of developing breast
cancer in the ipsilateral, compared to the contralateral breast;
(2) the histological and molecular similarities between LN and
ILC; and 3) the higher percentage of patients with a history of
LN who were found to develop ILC versus IDC com-
pared with the general population of women with breast
cancer [1, 3].
Therefore, LN has been defined as an entity that




Fig. 1 a Schematic drawing: 1 sagittal view of the breast showing
terminal duct-lobular units converging to lactiferous ducts and papilla; 2
a normal terminal duct-lobular unit (TDLU); 3 atypical lobular hyperpla-
sia (ALH), cellular proliferation in less than 50 % of acini; 4 lobular
carcinoma in situ (LCIS) cellular proliferation expandingmore than a half
of acini within a TDLU. (b) ALH in histological slice (haematoxylin–
eosin [H-E] stain, ×40 photomicrograph) demonstrating some normal
acini (*) and some lobules distended by cell proliferation (black
arrowheads). c LCIS in histological slice H-E, ×200, showing all acini
filled and distended by an uniform cell population
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obligate precursor lesion, as well as a risk indicator for
breast carcinoma [1, 3, 4, 6, 7].
The latest World Health Organisation classification of tu-
mour groups adopts the term LN without consideration of its
subtypes, ALH and LCIS [8].
Clinical features
The peak incidence of LN occurs at approximately 40–
50 years of age, and LN has a clear predominance in premen-
opausal women [1, 3]. Typically, multifocal and bilateral
lesions occur in up to 50 % and 30 % of cases, respectively
[1, 3, 4].
The true incidence of LN is not known due to the associ-
ated asymptomatic conditions and paucity of imaging find-
ings. LN usually does not have a characteristic imaging find-
ing, and most of the diagnoses are made based on incidental
features in excisional biopsies. Some studies have described
LN as an incidental finding in approximately 0.5–3.8 % of
benign breast lesion biopsies [1, 3].
Histopathology
The classic form of LCIS is diagnosed by the following
typical cellular patterns of small, uniform, and loosely cohe-
sive cells, with small nuclei, few pleomorphism, high nuclear-
to-cytoplasmic ratio and clear cytoplasm vacuoles known as
magenta bodies.
These cells fill acini in a discohesive pattern, respecting the
lobular architecture and they can extend along ducts infiltrat-
ing between the intact myoepithelial membrane and the ductal
epithelium in a classic arrangement known as the Pagetoid
spread [1, 4].
The immunochemistry study shows hormonal oestrogen
and progesterone receptors positive in 60–90 % of cases,
whereas the HER2 is usually not overexpressed [1].
Another important phenotypic characteristic is the lack of
E-cadherin expression in LN. E-cadherin is a transmembrane
glycoprotein involved in cell adhesion. This glycoprotein is
found on normal breast tissues and is strongly expressed in
ductal neoplasm [9]. Thus E-cadherin immunostaining is a
tool extremely useful for the differentiation of ductal and
Fig. 2 A 47-year-old woman;
percutaneous sample shows LN
(LCIS and ALH). The final
diagnosis was confirmed by
surgical biopsy. aMammography
in cranio-caudal view reveals a
focal asymmetry with subtle
architectural distortion in the
lateral quadrant. bHistological H-
E stain slice (×100) with marked
lobular distention and discohesive
cells. c Immunohistochemical
(IHC)—photomicrography
staining (×40) for e-cadherin
showing no expression in acini
involved by LN, on the left and
strong expression on preserved
acini, on the right (+). d IHC for
smooth muscle actin (×200), a
myoepithelial membrane marker.
There is strong reactivity for the
cytoplasm of basal membrane,
confirming an intact layer of
epithelial cells without invasion.
Notice the marked loss of cell
cohesion, without forming
papillary or cribriform
arrangement like in some of DCIS
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lobular carcinomas (sensitivity of 94 % and specificity of
98 %) (Fig. 2).
Other markers of LN include the cytoplasmic localisation
of p120-catenin and cytokeratin-34betaE12 [2].
Despite lacking a genetic signature, losses of chro-
mosomal material on 16q and gains on 1q were detected
in LN, similarly to columnar cell lesions (CCLs), low-
grade DCIS, tubular carcinoma (TC), and ILC. This
result suggests a common evolutionary pathway for
low-grade invasive and in situ lesions [1].
Imaging findings
Rendi et al. [10] studied 93 cases of LN and described
that, upon examination of the imaging findings, 74 %,
24 %, and 2 % of cases were detected by mammograms,
magnetic resonance imaging (MRI) and US, respectively.
Microcalcifications were the most common finding, oc-
curring in 69 % of cases, followed by pathological MRI
non-mass enhancement in 16 % (Fig. 3), masses in
14 %, and architectural distortions in 1 % of cases.
Mammography is the most sensitive method for di-
agnosing LN. The most typical finding is clusters of
punctate microcalcifications, seen in 30-50 % of cases
(Fig. 4). In fact, these clusters often are imaging find-
ings of associated lesions such as sclerosing adenosis,
columnar cell hyperplasia, and spherulosis [2, 4, 10]
adjacent to LN. However, it is important to emphasise
that majority of cases of LN have no imaging findings
and represents incidental findings in histopathological
specimens.
Histological variants
New molecular techniques combined with immunohisto-
chemical (IHC) markers have enabled the characterisation of
histological variants of LCIS. Pleomorphic lobular carcinoma
in situ (PLCIS) is an example of a new entity with a more
aggressive biological behaviour that may exhibit apocrine or
histiocytic differentiation and signet ring cells.
PLCIS typically has marked pleomorphism, and comprises
nuclei that are 2–4 times larger and more discohesive cell
pattern than those of classic form of LCIS. Necrosis and
calcifications are more frequent and may mimic DCIS, partic-
ularly the low-grade, solid DCIS [1, 2].
In contrast to its counterpart LCIS, PCLIS occurs predom-
inantly in postmenopausal women; in the majority of cases
patients present with clusters of microcalcifications on their
mammograms [6].
Immunohistochemistry is essential for the diagnosis of the
pleomorphic variants. These variants are characterised by a
combination of an absence of E-cadherin expression, a lower
expression of oestrogen and progesterone receptors, a higher
expression of HER2, a higher Ki67 index, and a higher pos-
itivity for cytokeratin GCDFP-15, compared with classic forms.
Currently, the finding of PLCIS in a percutaneous biopsy
indicates surgical excisionwith free margins [2]. However, the
most important feature of PLCIS is its association with ILC,
which is found in approximately 50 % of cases [6, 11].
Fig. 3 A 40-year-old woman with previous surgical resection of an ILC
15 months ago. Mammogram (not shown) with architectural distortion,
possibly surgical-related change. a MR image axial T1, 3rd min, post-
contrast media. There is a collection with low signal (+) and marked
wash-in enhancement surrounding the surgical area. A new surgical
exploration showed LN. b Photomicrograph H-E stain, ×200, pagetoid
ductal spread, with lobular proliferation, extending to the duct, between
the basal membrane and epithelial cell (arrowhead). In c the epithelial
cells show marked reactivity expression for e-cadherin and e-cadherin-
negative LCIS cells (*)
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Clinical management and recommendations
When a diagnosis of LN is made based on a core needle
biopsy (CNB), the risk of diagnosis underestimation is ap-
proximately 25 % [12, 13]. Even with satisfactory sampling
and radiological-pathological concordance, this risk can be up
to 9 % [14].
According to Middleton et al., the presence of a mass or
architectural distortions were the main findings associated
with the diagnostic underestimation of LN in percutaneous
breast biopsies [15].
Others studies have suggested that when histological sam-
ples with four or more ductulo-lobular units involved in LCIS
are present, there is a higher risk for underestimating the
diagnosis, as well as a higher association with invasive carci-
noma [11].
However, after diagnosis of LN, there is no consensus on
further management yet. Prospective studies are required to
define which patients really could benefit from surgical exci-
sion [3, 10, 11].
Surgical excision must be performed in cases in which
there is a presence of other risk factors for breast cancer,
pleomorphic lobular carcinoma in situ, equivocal histo-
pathological or immunohistochemical findings preventing
the differentiation between LN and DCIS, or radiological-
pathological discordance [1, 3, 11]. The main reasons
for radiological-pathological discordance are the occur-
rence of a lesion presenting as a mass or distortion,
microcalcifications that were not fully included in the
biopsy specimen and insufficient material for histopathologi-
cal diagnosis [1, 3].
However the majority of authors, based on the upgrade rate
to malignancy, support that surgical excision should be done
in all LN diagnosis [11, 14].
Nevertheless, it is important to consider that when a diag-
nosis of LN is made after an excisional biopsy or when it is an
incidental finding of an oncologic surgery, no free surgical
margins are required, except in cases of a pleomorphic sub-
type of LN.
The use of radiation therapy and endocrine chemoprophy-
laxis are controversial and there is no consensus on their use
and efficacy [3].
A proposed follow-up for patients with a prior diagnosis of
LN is a clinical examination every 6 months and an annual
mammogram starting from the date of diagnosis. For women
with no other associated risk factors, there is no formal indi-
cation for an MRI screening [3].
Fig. 4 A 43-year-old woman: routine mammography for screening. a
Additional cranio-caudal magnified views showing new cluster of
microcalcifications. The patient underwent a percutaneous biopsy and,
after that, surgical excision of the residual microcalcifications. b Histol-
ogy confirms a LN, with less than 50% of acini involved. Normal lobular
acini (+) and ALH (*) are easily seen
Fig. 5 ILC classic type, H-E photomicrographs. a Magnification ×40.
Small cells infiltrating breast stroma surrounding benign breast tissues in
a targeted manner (*). b Magnification ×200, showing cells arranged in
lines, with interspersed fibrosis and inflammation. c Magnification
×1,000, in oil immersion, cells lying in an “Indian file” manner and with
cytoplasmactic vacuoles, Magenta Bodies (arrows)
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Invasive lobular carcinoma
Background
In 1941, Foote and Stewart [5] described LCIS and found
similarities between their cytological patterns and those of
ILC, highlighting the common origin of the terminal duct-
lobular unit for both conditions. When diagnosis is based
strictly on the criteria of Foote and Stewart, invasive
lobular carcinoma usually constitutes 5 % or less of breast
carcinomas [1].
However, currently, less strict criteria are employed, and
ILC corresponds to approximately 5–15 % of all breast carci-
nomas, representing the second most common type of breast
malignancy [4].
The classic form of ILC is the most common subtype and
may coexist with LN in up to 90 % of cases [16]. Other
subtypes, including the alveolar, solid, pleomorphic and
tubulolobular subtypes, have similar cellular features but dif-
ferent structural arrangements, molecular aspects and clinical
behaviours.
Clinical features
The peak incidence of ILC occurs in post-menopausal women
in their 50s and 60s, with a mean age that is approximately 1–
Fig. 7 A 42-year-old woman with ILC. a and b Cranio-caudal and
oblique views showing an irregular mass, with spiculated margins and
isodense to parenchyma (*). There is a nipple retraction (arrow). The
mass is much more conspicuous in cranio-caudal view
Fig. 8 A 73-year-old woman with ILC. a US image depicts an irregular,
hypoechoic mass, with indistinct margins and distal attenuation of sound.
bMagnified cranio-caudal view also shows an irregular mass associated
to microcalcifications
Fig. 6 A 56-year-old woman with ILC. Mammography in oblique views
showing global asymmetry with increased parenchymal density, archi-
tectural distortion and loss of volume in the left side
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Fig. 9 A 45-year-old woman
with ILC. a and bMR images
from right breast, respectively, T2
with fat suppression, sagittal
reformation from T1 volumetric,
post-contrast images, showing an
irregular mass (arrows), with
spiculated margins, seen adjacent
to an intact breast implant. After
IV contrast, there is a uniform,
progressive enhancement, until
delayed phases, typical of
invasive lobular neoplasia. (c)
Kinetic curve type 1
Fig. 10 A 56-year-old woman. a
MRT1-post-contrast subtracted
sagittal image showing a non-
mass enhancement, with
segmental distribution, in an
extension larger than seen on
mammogram view (dashed line).
b) MR—axial STIR demonstrates
cutaneous oedema (arrowhead)
and axilar adenopathy (+). c H-E
×200, showing tumour
embolisation in a dermal
lymphatic (star). d Sentinel
lymph node biopsy with cortical
invasion (*), in H-E stain, ×40
Insights Imaging (2014) 5:183–194 189
3 years older than the mean age of women with invasive
ductal carcinoma [17].
A common clinical presentation is a palpable mass or
thickening of the breast tissue, often with imprecise delimita-
tion and size underestimation at clinical examination.
A marked characteristic of ILC is the presence of
synchronous neoplastic foci, occurring in the same or in
the contralateral breast (multifocality/multicentricity),
which happens more frequently than in IDC. The relative
risk to bilaterality is 1.5 compared with invasive ductal
carcinoma [17].
The pattern of haematogenic metastases associated with
ILC shows some peculiarities. There is a higher rate of me-
tastasis in bones, gastrointestinal tract, uterus, meninges, ova-
ries and serosas, as well as a lower rate of lung metastases, in
ILC compared with IDC [18].
Histopathology
The histology of ILC is similar to that of LN; specifi-
cally, the cells are small, discohesive and uniform, with
a small cytoplasm, cytoplasmic Magenta Bodies and a
low mitotic index [2].
Neoplastic cell proliferation occurs, preserving the
breast parenchymal architecture and associated to a low
level of host desmoplastic reactions. The histological di-
agnosis is based on two classic patterns of the arrangement
of neoplastic cells in the glandular stroma: (1) single-file
linear cords dispersed throughout a fibrous tissue (so-
called Indian file) and (2) concentric cell arrangements
involving ducts and lobules, described as a “targetoid”
appearance (Fig. 5).
Although it was initially questioned, the current grading
of ILC is performed according to the Nottingham classifi-
cation, which demonstrates a correlation between grading,
survival and disease-free intervals [2]. Approximately
76 % of lesions are grade II; usually, most of the grade
III lesions arise from variants of ILC (non-classic
subtypes). The mitotic index is the single most important
predictor of prognosis [2].
Most (90 %) of the lesions have hormonal receptors, but
HER2 overexpression is rarely seen in ILC [19, 22].
The absence or discrete expression of E-cadherin is the
major IHC marker of the differentiation between ILC and
invasive ductal carcinoma. Occasionally, the extension of
an IDC to the interior of a lobule, called “lobular
cancerisation” may mimic an ILC. In this situation, E-
cadherin staining is crucial for obtaining the correct
diagnosis.
Although there is no specific genetic profile for ILC,
one of the main genomic changes is the loss of material in
the short arm of chromosome 16, the location of the gene
for E-cadherin. The E-cadherin gene has been postulated as
a possible tumour gene suppressor with a large number of
possible mutations and is also found in ILC and low-grade
DCIS [20]. This finding suggests a potential role for E-
cadherin in the pathogenesis of breast cancer [23]. Other
IHC markers that may be used for ILC characterisation
include cathepsin D, cyclin D1 and Bcl-2 intracytoplasmic
localisation of p120-catenin [2, 5].
Imaging findings
Mammography
Typically, ILC has low mammographic sensitivity, varying
from 57 to 79 %, and is one of the most important causes of
false-negative mammograms, with rates up to 20 % [16, 21].
The histological features of ILC, such as a lack of stromal
desmoplasia and an infiltrative growth pattern, account for the
Fig. 11 A 49-year-old woman with bilateral ILC. a and bMammograph-
ic oblique views for screening. A dense breast is seen, with a small
irregular lesion, indistinct margins in the central right breast (dotted
line). Core needle biopsy confirmed an ILC andMR examwas requested.
Sagittal views, T1 post-contrast, from right (c) and left breasts (d)
confirming the right lesion seen onmammography (larger inMR images).
However, another lesion is seen in contralateral breast, also with irregular
margins and strong enhancement (circle). The kinetic curves for index
lesion and synchronous contralateral mass were type 3 and 2 curves,
respectively, not showed
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low sensitivity of mammography due to the associated
subtle findings and underestimation of the size of lesions
[21–23]. Lesions as large as 5.0 cm may be missed in
mammography if they exhibit similar density to breast
parenchyma.
Subtle presentation, including focal asymmetry and
architectural distortions, is more common in ILC than
in IDC [24]. In larger lesions, a classical presentation of
increased parenchymal density and a reduction of breast
volume may be found (Fig. 6) [16]. However, the most
common finding of ILC is an irregular mass, with
indistinct or spiculated margins (Fig. 7). Calcifications
are less frequent in ILC, occurring in about 10-20 % of
cases [25].
Ultrasound
Ultrasonography plays an essential role in the evaluation of
ILC, with sensitivity ranging from 81 to 83 % [26]. It
exhibits a higher accuracy than mammography for lesion
measurements , de tec t ions of mul t i foca l i ty and
multicentricity and lymph node assessments [16]. It is the
primary method for guiding biopsies of index lesions and
adenopathy [26, 27], as well as for the assessment of
palpable lesions not seen on mammograms. Up to 73 %
of carcinomas not seen on mammograms may be detected
through this method [26].
The sonographic findings of ILCmay be similar to those of
IDC. The most common finding is a hypoechoic, irregular
mass with indistinct margins in approximately 85 % of cases
(Fig. 8) [28]. For the detection of small lesions (smaller than
1 cm), the use of high-frequency transducers coupled with
harmonics may enhance the detection of microlobulations and
spiculations, thereby improving diagnostic accuracy [25].
Fig. 12 Tubulo-lobular variant in
a 59-year-old woman with non-
palpable lesion. a and bMR
images, axial STIR and MIP
reconstruction from T1 post-
gadolinium, showing an irregular
mass, spiculated margins in the
transition of outer quadrants of
right breast. There is a clear ductal
extension (trace) towards the
nipple. c Histological slice, e-
cadherin stain, ×100,
demonstrating neoplastic cells in
the classic pattern of slender
strands interposed to tubular
structures (*) with no expression
for e-cadherin
Table 1 Histological variants of invasive lobular carcinoma
Subtype Histological features
Alveolar Small cells arranged in more-or-less globular
aggregate of 20 or more cells separated by
thin bands of fibrous stroma.
Tubulo-lobular Neoplastic cells form tubular, glandular structures.
The best prognosis among all forms.
Solid Solid sheets of uniform small cells showing
lobular morphology.
There are more pleomorphism and higher
frequency of mitoses.
Pleomorphic The more aggressive and worst prognosis.
The histological pattern may mimic an
undifferentiated ductal carcinoma. Cells are
larger due to irregular nuclei with prominent
nucleoli.
Mitotic figures are frequent, disperse or in line,
throughout the breast stroma. Apocrine or
histiocytoid differentiation is common.
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A typical finding of ILC is the lower frequency of “taller
than wider” lesions compared with those found in IDC.
Cawson et al. [29] attributed the preferential parallel orienta-
tion of ILC in the US images to the infiltrative growth pattern
that follows the anatomical breast parenchymal planes.
Although atypical for a malignant mass, hyperechoic le-
sions are 10 times more common in ILC than in other types of
breast malignancies [29]. The posterior acoustic shadow with-
out a definite mass may be a presentation of ILC [28].
Magnetic resonance imaging
MRI shows great sensitivity for ILC, ranging from 83
to 100 % [16]. The most common MRI finding associ-
ated with ILC is an irregular and spiculated mass-like
lesion (Fig. 9), followed by a non-mass lesion in 20–
40 % of cases (Fig. 10) [30].
The kinetics of ILC in dynamic post-contrast images show
a slow-rising signal intensity, characteristic of a type I or
progressive curve, which is the most common finding in
kinetics analysis. Peripheral oedema and the rim pattern of
enhancement are less common findings [30].
Compared with mammography and US, MRI is the best
option for determining the size of lesions, although overesti-
mation occurs in up to 20% of cases. Overestimation has been
associated mainly with the presence of LCIS. Despite being
less common, diagnostic underestimations may occur and are
frequently associated with larger lesions and higher patholog-
ical grades.
In addition, MRI shows a high accuracy for the detection of
synchronous lesions in the same or contralateral breast, rang-
ing from 80 to 90 % (Fig. 11) [30].
A more precise determination of the burden of lesions
allows for better surgical planning (mastectomy versus con-
servative techniques) and is fundamental for the indication
and planning of neoadjuvant chemotherapy [31].
Despite the evidence of the high sensitivity of MRI for the
detection of ILC, its role in preoperative staging is still con-
troversial. In fact, no study has confirmed an improvement in
overall survival. A possible explanation for this result is that
MRI shows small synchronous lesions that would be effec-
tively treated by adjuvant therapies (chemotherapy and/or
radiotherapy) without the need for additional surgical proce-
dures. However, most of the synchronous lesions diagnosed
by MRI share histological characteristics related to
Fig. 13 A 61-year-old woman with PILC. a Oblique view showing an
irregular, hyperdense mass in axillar extension (arrow). b US images
depict an irregular, hypoechoic, parallel lesion, with angulated margins
(calipers). c Photomicrograph H-E stain, ×200, the intense pleomorphism
is evident, along with large nuclei and heterogeneous chromatin
(arrowhead)
Fig. 14 A 61-year-old womanwith right breast lump, diagnosed as mixed
carcinoma, ducto-lobular. a Oblique mammography view showing an
irregular, spiculated mass. b US showing an irregular, non-parallel mass,
surrounded by an echogenic halo. c H-E stain ×100, LCIS is seen in the
right upper corner (arrow), ILC in the centre (*) andDCIS (arrowheads) at
the bottom of the figure (IDC not present in the same slice)
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aggressiveness and a prognosis similar to that of the index
lesions [30]. Furthermore, the impact of a lesion’s over-
estimation by MRI when deciding and planning the
surgical approach is questionable, as this could arguably
lead to overtreatment [31].
Current evidence has shown changes in the clinical man-
agement of patients who had a preoperative breast MRI [17]
and the clear benefit of a minor rate of surgical re-assessment
in patients who underwent conservative surgeries. Mann et al.
[32] retrospectively evaluated the role of preoperative MRI in
the treatment of ILC and concluded that MRIs significantly
reduced the rate of re-assessment in breast conservation sur-
geries, without increasing the number of mastectomies.
Prognostic factors and clinical management
Although ILC has some good prognostic factors, such as
lower grades, lower mitotic indexes, positive hormonal recep-
tors and a lack of HER2 overexpression, there is no difference
in the survival rates of patients with these two histological
types [26], which may be justified by the fact that, usually,
ILC is diagnosed in more advanced staging than IDC [33].
It is well known that when conservative procedures are
chosen, free surgical margins are less common for ILC than
for IDC; thus, the rate of re-excision is significantly higher for
ILC treated with conservative surgeries [34]. Mastectomy as
an option for re-assessment is used in 16–48 % of patients
[30]. However, when surgical margins are free in conservative
surgeries, there is no difference in local recurrence, disease-
free survival or overall survival compared with IDC [26].
Accordingly, the indications for surgical treatment, radiother-
apy and chemotherapy do not differ between ILC and IDC [2].
Endocrine therapy is often used in women with ILC, given
their high proportion of hormonal receptor expression [2].
Histological variants
The histological variants of ILC exhibit the typical cytological
features of lobular carcinoma in the classic form: uniform
neoplastic cells that have round or notched ovoid nuclei,
thin-rimmed cytoplasms with an occasional intracytoplasmic
lumen and immunohistochemically negative E-cadherin. The
main differences between the variants arise from their growth
patterns and structural arrangements.
The main variants include the alveolar, solid, tubulolobular
(Fig. 12) and pleomorphic forms. Their main characteristics
are summarised in Table 1. Based on the imaging findings, the
differentiation of various subtypes of ILC is not possible. This
diagnosis is made solely through histology, and its prognosis
is variable [2, 5].
Pleomorphic invasive lobular carcinoma (PILC), although
rare, is the most clinically important variant due to its aggres-
sive biological behaviour. Although it shares genetics and
IMC features with the classical form of ILC, including its
positivity for hormonal receptors and its lack of E-cadherin
expression, the diagnosis of PILC is related to an overexpres-
sion of HER2, a more advanced clinical staging, a higher
incidence of multicentricity, a higher early recurrence and a
slightly higher overall recurrence [35]. The radiological find-
ings of PILC are similar to those of classic ILC, and a mass
with spiculated or indistinct margins is the most prevalent
feature, followed by architectural distortions (Fig. 13) [35].
Tumours with a mixed ductal and lobular features account
for 2–6 % of breast carcinomas, exhibiting features that are
more related to ILC and a prognosis that is more dependent on
phenotypic characteristics, which are generally better than
those of pure IDC (Fig. 14) [18].
Conclusion
LN includes AHL and LCIS, and is a non-obligate precursor
lesion and risk factor for breast cancer. The findings of LN in
percutaneous biopsies may be underestimated in up to 24% of
cases, prompting excisional biopsies when there is a
radiological-pathological discordance or the presence of other
risk factors or PLCIS variant.
ILC is the second most common histological type of breast
cancer. Mammography has a lower sensitivity for ILC than it
does for IDC, and the typical subtle findings may lead to false-
negative exams. MRI is more accurate for determining lesion
sizes and detecting synchronic lesions. The histological vari-
ants of ILC are indistinguishable from the classic type by
imaging alone, even for the pleomorphic variant, which is
the most aggressive ILC variant.
In conclusion, LN and ILC are two distinct conditions that
share similar cellular characteristics, but with different prog-
nosis. It is important for radiologists be familiar with evolving
pathological concepts of LN and ILC to improve diagnostic
accuracy and confidently recommend clinical follow-up or
surgical management.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
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